XZXiaofen Zhang

Xiaofen Zhang

*This is an algorithmically generated author record based on publicly available information.

Xiaofen Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Hangyu Jiang

    Department of Pharmacy, The Second Clinical Medical College of North Sichuan Medical College, Nanchong, China

    3 shared publications
  • Kang Liu

    Institute of Tissue Engineering and Stem Cells, The Second Clinical Medical College of North Sichuan Medical College, Nanchong, China

    2 shared publications
  • Lin Li

    Department of Pharmacy, The Second Clinical Medical College of North Sichuan Medical College, Nanchong, Sichuan, China

    2 shared publications
  • Yueming Chu

    Department of Pharmacy, The Second Clinical Medical College of North Sichuan Medical College, Nanchong, China

    2 shared publications
  • Yuqi Li

    Department of Pharmacy, Nanchong Traditional Chinese Medicine Hospital, Nanchong, China

    2 shared publications
  • Danqun Huo

    School of Bioengineering, Chongqing University, China

    1 shared publication

Latest Publications

  • Open Access

    A comprehensive review of the anticancer effects of decursin

    by Yueming Chu, Qiang Yuan, Hangyu Jiang, Liang Wu, Yutao Xie, Xiaofen Zhang, Lin Li

    Cancer is a globally complex disease with a plethora of genetic, physiological, metabolic, and environmental variations. With the increasing resistance to current anticancer drugs, efforts have been made to develop effective cancer treatments. Currently, natural products are considered promising cancer therapeutic agents due to their potent anticancer activity and low intrinsic toxicity. Decursin, a coumarin analog mainly derived from the roots of the medicinal plant Angelica sinensis, has a wide range of biological activities, including anti-inflammatory, antioxidant, neuroprotective, and especially anticancer activities. Existing studies indicate that decursin affects cell proliferation, apoptosis, autophagy, angiogenesis, and metastasis. It also indirectly affects the immune microenvironment and can act as a potential anticancer agent. Decursin can exert synergistic antitumor effects when used in combination with a number of common clinical anticancer drugs, enhancing chemotherapy sensitivity and reversing drug resistance in cancer cells, suggesting that decursin is a good drug combination. Second, decursin is also a promising lead compound, and compounds modifying its structure and formulation form also have good anticancer effects. In addition, decursin is not only a key ingredient in several natural herbs and dietary supplements but is also available through a biosynthetic pathway, with anticancer properties and a high degree of safety in cells, animals, and humans. Thus, it is evident that decursin is a promising natural compound, and its great potential for cancer prevention and treatment needs to be studied and explored in greater depth to support its move from the laboratory to the clinic.


  • Open Access

    Chaetocin exhibits anticancer effects in esophageal squamous cell carcinoma via activation of hippo pathway

    by Lin Li, Hangyu Jiang, Yuqi Li, Xiaochong Xiang, Yueming Chu, Jie Tang, Kang Liu, Danqun Huo, Xiaofen Zhang

    Dysfunction of the Hippo pathway is common in esophageal squamous carcinoma (ESCC). Chaetocin, a small molecular compound isolated from the marine fungus, exhibits potent anticancer effects. However, the anticancer effects of chaetocin on ESCC and its potential relationship to Hippo pathway remain unclear. Here, we demonstrated that chaetocin dramatically inhibited the proliferation in ESCC cells by causing cycle arrest in the M phase and activating the caspase-dependent apoptosis signaling pathway in vitro, and we also found that chaetocin induced the accumulation cellular reactive oxygen species (ROS). The RNA-seq analysis indicated that the Hippo pathway is one of the most enriched pathways after chaetocin treatment. We further revealed that chaetocin triggered the activation of Hippo pathway in ESCC cells, which is characterized by elevated phosphorylation levels of almost all core proteins in Hippo pathway, such as MST1 (Thr183), MST2 (Thr180), MOB1 (Thr35), LAST1 (Thr1079 and Ser909) and YAP (Ser127), ultimately leading to decreased nuclear translocation of YAP. Moreover, the MST1/2 inhibitor XMU-MP-1 not only partially rescued the inhibitory effect chaetocin-induced proliferation, but also rescued the chaetocin-induced apoptosis in ESCC cells. Furthermore, in vivo results confirmed the antitumor effect of chaetocin and its relationship with Hippo pathway. Taken together, our study demonstrates that chaetocin exhibits anticancer effects in ESCC via activation of Hippo pathway. These results provide an important basis for further research of chaetocin as a potential candidate for ESCC treatment.


  • Open Access

    Chaetocin: A review of its anticancer potentials and mechanisms

    by Hangyu Jiang, Yuqi Li, Xiaocong Xiang, Zhili Tang, Kang Liu, Qiang Su, Xiaofen Zhang, Lin Li